Cardiovascular biomarkers in chronic kidney disease

Journal of Medical Biochemistry

Volumn 29, Issue 4, 2010, Pages 298-303

  Derić, Mirjana ^a   Čabarkapa, Velibor S ^a  

^a Clinical Centre of Vojvodina   (Serbia)

Author keywords

biochemical markers; cardiovascular disease; chronic renal failure

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; NATRIURETIC PEPTIDE RECEPTOR A; NITRIC OXIDE SYNTHASE; PHOSPHORUS;

ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MALNUTRITION; OXIDATIVE STRESS; REVIEW; UREMIA;

ANGINA;

EID: 77958108759     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-010-0033-8     Document Type: Review

References (50)

1. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53: 2129-40.
2. Wang AYM, Chan DTM, Lai KN. Cardiovascular disease in end-stage renal disease. Hong Kong J Nephrol 2006; 8: 10-16.
3. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-39.
4. Girndt M, Seibert E. Premature cardiovascular disease in chronic renal failure (CRF): A model for an advanced ageing process. Experimental Gerontology (2010), doi: 10.1016/j.exger.2010.04.003.
5. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
6. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classifications, concentrations and interindividual variability. Kidney Int 2003; 63: 1934-43.
7. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P. Free p-cresol is asso ciated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-80.
8. Glorieux G, Cohen G, Jankowski J, Vanholder R. Platelet/leukocyte activation, inflammation, and uremia. Semin Dial 2009; 22: 423-7.
9. Igarashi K, Ueda S, Yoshida K, Kashiwagi K. Poly amines in renal failure. Amino acids 2006; 31: 477-83.
10. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thromb Res 2009; 124: 452-7.
11. Günthner T, Jankowski V, Kretschmer A, Nierhaus M, Van der Giet M, Zidek W. Endothelium and vascular smooth muscle cells in the context of uremia. Semin Dial 2009; 22: 428-32.
12. Barreto FC, Barreto D V, Liabeuf S, Drüeke TB, Massy ZA. Effects of uremic toxins on vascular and bone remodeling. Semin Dial 2009; 22: 433-7.
13. Thornalley PJ, Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009; 22: 400-4.
14. Mory Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, et al. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29: 18-24.
15. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, et al. Molecular mechanism for elevation of asymmetrical dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176-83.
16. Wagner C. Cystatin C, renal function and cardiovascular risk. Journal of Medical Biochemistry 2008; 27: 426-31.
17. Eriksson P, Deguchi H, Samnegard A, Lundman P, Boquist S, Tornvall P, et al. Human evidence that the cystatin c gene is implicated in focal progression of coronary artery disease. Atheroscler Thromb Vasc Biol 2004; 24: 551-7.
18. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
19. Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago J V, Hmiel P, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrin Metab 1997; 82: 847-50.
20. Leskinen Y, Lehtimäki T, Loimaala A, Huhtala H, Salenius J P, Oja SS, et al. Homocysteine and carotid atherosclerosis in chronic renal failure the confounding effect of renal function. Atherosclerosis 2004; 175: 315-23.
21. Perna A F, Ingrosso D, Violetti E, Luciano AG, Sepe I, Lanza D, et al. Hyperhomocysteinemia in uremia a red flag in a disrupted circuit. Semin Dial 2009; 22: 351-6.
22. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease not validated. J Am Coll Cardiol 2006; 48: 914-23.
23. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59.
24. Van Kimmenade RRJ, Januzzi JL Jr, Bakker JA, Houben AJ, Ronnenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide. A mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009; 53: 884-90.
25. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta 2010: 411: 936-9.
26. Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Semin Dial 2009; 22: 363-8.
27. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009; 22: 357-62.
28. Fellah H, Hammami MB, Feki M, Boubaker K, Abdallah TB, Lacour B, et al. Predictors for cardiovascular morbidity and overall mortality in Tunisian ESRD patients: a six year prospective study. Clin Biochem 2009; 42: 648-53.
29. Ketteler M, Bongartz P, Westenfeld W, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-33.
30. Panichi V, Manca Rizza G, Taccola D, Paoletti S, Mantuano E, Migliori M, et al. C-reactive protein in patients on chronic hemodialysis with different techniques and different membranes. Biomed Pharmacother 2006; 60: 14-17.
31. Bayes B, Pastor C, Bonal J, Junca J, Hernandez JM, Riutort N, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in hemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-12.
32. Vidt DG. Inflammation in renal disease. Am J Cardiol 2006; 97: Suppl 1: 20-7.
33. Honda H, Quereshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin-6, and fetuin-A as predictors of malnutrition, cardiovascular disese, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-48.
34. Wanner C, Drechsler C, Krane V. C-reactive protein and uremia. Semin Dial 2009; 22: 438-41.
35. Bisoendial RJ, Kastelein JJP, Stroes ESG. C-reactive protein and atherogenesis: From fatty streak to clinical event. Atherosclerosis 2007; 195: e10-18.
36. Ulrich C, Heine GH, Seibert E, Fliser D, Girndt M. Circulating monocyte subpopulations with high expres sion of angiotensin conversion enzyme predict mortality in patients with end-stage renal disease. Nephrol Dial Transplant 2010; 25: 2265-72.
37. Ickihawa I, Kiyama S, Yoshioka T. Renal antioxidant enzy mes: their regulation and function. Kidney Int 1994; 45: 1-9.
38. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thévenin M, Jaudon MC, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-53.
39. Valentini J, Grotto D, Paniz C, Roehrs M, Burg G, Garcia SC. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother 2008; 62: 378-82.
40. Euchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Clerc M. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamin A, E and iron status. Free Radic Biol Med 1994; 16: 339-46.
41. Olak E, Majkić-Singh N. The effect of hyperglycemia and oxidative stress on the development and progress of vascular complications in type 2 diabetes. Journal of Medical Biochemistry 2009; 28: 63-71.
42. Annuk M, Zilmer M, Lind L, Linde T, Fellström B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-52.
43. Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001; 16: 2135-7.
44. Grieve DJ, Shan AM. Oxidative stress in heart failure: more than just damage. Eur Heart J 2003; 24: 2161-3.
45. Urević-Mirković T, Urić S. Lipid metabolism disturbance in kidney diseases. In: Erić M, Stokić E, Todorovićilas Lj. Hyperlipoproteinemias-current aspects, Physicians Society of Vojvodina-Serbian Physicians Society, Novi Sad 2005: 255-60.
46. Prinsen B, De Sain van der Velden M, De Koning E, Koomans H, Berger R, Rabelink T. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int 2003; 63: 121-4.
47. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low density lipoprotein subfraction profiles during the progression of chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281-7.
48. Cauza E, Kletzmaier J, Bodlaj G, Dunky A, Herrman W, Kostner K. Relationship of non-LDL-bound apo (a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003; 18: 1568-72.
49. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008; 102: 47-53.
50. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-93.